“The Centers for Disease Control and Prevention (CDC) on Thursday recommended the first-ever monoclonal antibody marketed as a defense for all newborns against respiratory syncytial virus, or RSV.
Beyfortus, also known as nirsevimab, is produced by pharma giants Sanofi and AstraZeneca…
According to The Associated Press (AP), the drug will be offered as a ‘one-time shot for infants born just before or during the RSV season and for those less than 8 months old before the season starts,’ and for some high-risk 8-19-month-old infants…
Several infant deaths — 12 in all — were reported during the clinical trial, which the U.S. Food and Drug Administration (FDA) claimed during a June review were “unrelated” to the antibody. On Thursday, Jones repeated this claim during the ACIP meeting, stating that “no RSV-associated deaths were recorded.”
CNBC reported in June that of the 12 infants, ‘Four died from cardiac disease, two died from gastroenteritis, two died from unknown causes but were likely cases [of] sudden infant death syndrome, one died from a tumor, one died from COVID, one died from a skull fracture, and one died of pneumonia.’”